Financials

As this is now a publicly traded company on the US stock exchange, all financials are disclosed on the company website.   The company is still in the investor runway phase however the potential is looking up year over year.  The stock price itself is way lower than its IPO (see tickr AKLI), but I believe that to be more a function of timing that company performance.   "In the post-pandemic economy, with rising interest rates and record inflation numbers, SPAC-linked IPOs decreased dramatically" (Kabir, 2023).  This essentially means IPOs were overvalued when money was dumped into the market during the pandemic.  The company revenues are growing YOY but it is still unclear if there is a long term path to continued growth, success and what that may ultimately look like. 

“There’s no playbook for the commercialization of a product like EndeavorRx,”  Ashleigh Chung, Akili’s head of commercial strategy and operations, wrote in an email.  (Reuter, 2022)